Natco Pharma Ltd. witnessed a sharp decline of 16% in its stock price following a disappointing performance in the third quarter of FY25. The pharmaceutical company’s consolidated net profit fell to Rs 133 crore in the quarter ending December 31, 2024, marking a steep decline from Rs 212.70 crore in the same period last year, as per an exchange filing on Wednesday.
The company’s revenue dropped by 37.4% to Rs 474.80 crore, down from Rs 758.60 crore recorded in Q3 FY24. Additionally, its earnings before interest, tax, depreciation, and amortization (EBITDA) plummeted 86% to Rs 38.79 crore, compared to Rs 268.10 crore in the year-ago quarter.
Margins also took a severe hit, narrowing to 8.2% in the October-December 2024 quarter, significantly lower than 35.3% reported in Q3 FY24. The poor financial results triggered a heavy sell-off, pushing Natco Pharma shares down 16% in intraday trading.
Natco Pharma’s stock opened at ₹1,039.10, reaching a high of ₹1,051.25 and a low of ₹992.15. The stock remains volatile, trading below its 52-week high of ₹1,639.00 but above its 52-week low of ₹829.60.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
